TY - JOUR
T1 - Occludin as a functional marker of vascular endothelial cells on tube-forming activity
AU - Kanayasu-Toyoda, Toshie
AU - Ishii-Watabe, Akiko
AU - Kikuchi, Yutaka
AU - Kitagawa, Hiroko
AU - Suzuki, Hiroko
AU - Tamura, Hiroomi
AU - Tada, Minoru
AU - Suzuki, Takuo
AU - Mizuguchi, Hiroyuki
AU - Yamaguchi, Teruhide
N1 - Funding Information:
The authors thank Tokyo Red Cross Cord Blood Center for their kind cooperation. This work was supported in part by a grant-in-aid for Health and Labor Science Research (H17-SAISEI-021 and H20-SAISEI) from the Japanese Ministry of Health, Labor and Welfare, and in part by a grant-in-aid for Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation.
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Cell therapy using endothelial progenitor cells (EPCs) is a promising strategy for the treatment of ischemic diseases. Two types of EPCs have been identified: early EPCs and late EPCs. Late EPCs are able to form tube structure by themselves, and have a high proliferative ability. The functional marker(s) of late EPCs, which relate to their therapeutic potential, have not been fully elucidated. Here we compared the gene expression profiles of several human cord blood derived late EPC lines which exhibit different tube formation activity, and we observed that the expression of occludin (OCLN) in these lines correlated with the tube formation ability, suggesting that OCLN is a candidate functional marker of late EPCs. When OCLN was knocked down by transfecting siRNA, the tube formation on Matrigel, the S phase + G2/M phase in the cell cycle, and the spheroid-based sprouting of late EPCs were markedly reduced, suggesting the critical role of OCLN in tube formation, sprouting, and proliferation. These results indicated that OCLN plays a novel role in neovascularization and angiogenesis.
AB - Cell therapy using endothelial progenitor cells (EPCs) is a promising strategy for the treatment of ischemic diseases. Two types of EPCs have been identified: early EPCs and late EPCs. Late EPCs are able to form tube structure by themselves, and have a high proliferative ability. The functional marker(s) of late EPCs, which relate to their therapeutic potential, have not been fully elucidated. Here we compared the gene expression profiles of several human cord blood derived late EPC lines which exhibit different tube formation activity, and we observed that the expression of occludin (OCLN) in these lines correlated with the tube formation ability, suggesting that OCLN is a candidate functional marker of late EPCs. When OCLN was knocked down by transfecting siRNA, the tube formation on Matrigel, the S phase + G2/M phase in the cell cycle, and the spheroid-based sprouting of late EPCs were markedly reduced, suggesting the critical role of OCLN in tube formation, sprouting, and proliferation. These results indicated that OCLN plays a novel role in neovascularization and angiogenesis.
KW - late endothelial progenitor cell
KW - occludin
KW - therapeutic angiogenesis
UR - http://www.scopus.com/inward/record.url?scp=85032940070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032940070&partnerID=8YFLogxK
U2 - 10.1002/jcp.26082
DO - 10.1002/jcp.26082
M3 - Article
C2 - 28681912
AN - SCOPUS:85032940070
SN - 0021-9541
VL - 233
SP - 1700
EP - 1711
JO - Journal of Cellular Physiology
JF - Journal of Cellular Physiology
IS - 2
ER -